Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bellerophon Therapeutics Inc BLPH

Healthcare Biotechnology
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an... see more

Recent & Breaking News (GREY:BLPH)

Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

GlobeNewswire May 26, 2021

Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results

GlobeNewswire May 11, 2021

Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

GlobeNewswire March 11, 2021

Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 2, 2021

Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

GlobeNewswire January 4, 2021

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease

GlobeNewswire December 1, 2020

Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19

GlobeNewswire November 23, 2020

Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference

GlobeNewswire November 11, 2020

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results

GlobeNewswire November 5, 2020

Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences

GlobeNewswire October 29, 2020

Bellerophon to Present at Two September Investor Conferences

GlobeNewswire September 14, 2020

Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Officer

GlobeNewswire August 11, 2020

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results

GlobeNewswire August 5, 2020

Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results

GlobeNewswire July 15, 2020

Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

GlobeNewswire July 13, 2020

Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes

GlobeNewswire June 29, 2020

Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares

GlobeNewswire May 22, 2020

Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

GlobeNewswire May 19, 2020

Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire May 18, 2020

Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results

GlobeNewswire May 11, 2020